Abuse-Deterrent Formulations of Prescription Opioid Analgesics in the Management of Chronic Noncancer Pain

References

• Goldberg DS , McGeeSJ . Pain as a global public health priority . BMC Public Health11 , 770 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Johannes CB , LeTK , ZhouXet al. The prevalence of chronic pain in United States adults: results of an Internet-based survey . J. Pain11 , 1230 – 1239 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Nakamura M , NishiwakiY , UshidaT , ToyamaY . Prevalence and characteristics of chronic musculoskeletal pain in Japan . J. Orthop. Sci.16 , 424 – 432 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Reid KJ , HarkerJ , BalaMMet al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact . Curr. Med. Res. Opin.27 , 449 – 462 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Henderson JV , HarrisonCM , BrittHCet al. Prevalence, causes, severity, impact, and management of chronic pain in Australian general practice patients . Pain Med.14 , 1346 – 1361 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Häuser W , WolfeF , HenningsenPet al. Untying chronic pain: prevalence and societal burden of chronic pain stages in the general population – a cross-sectional survey . BMC Public Health14 , 352 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dueñas M , SalazarA , OjedaBet al. A nationwide study of chronic pain prevalence in the general Spanish population: identifying clinical subgroups through cluster analysis . Pain Med.16 , 811 – 822 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Inoue S , KobayashiF , NishiharaMet al. Chronic pain in the Japanese community – prevalence, characteristics and impact on quality of life . PLoS ONE10 , e0129262 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine . Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research . The National Academies Press , Washington, DC, USA ( 2011 ).
   Google Scholar
• Global Burden of Disease Study 2013 Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet386 , 743 – 800 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Chou R , FanciulloGJ , FinePGet al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain . J. Pain10 , 113 – 130 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Smith SM , DartRC , KatzNPet al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations . Pain154 , 2287 – 2296 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Manchikanti L , HelmS , FellowsBet al. Opioid epidemic in the United States . Pain Physician15 ( Suppl. ), ES9 – ES38 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Meyer R , PatelAM , RattanaSKet al. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States . Popul. Health Manag.17 , 372 – 387 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jones CM , MackKA , PaulozziLJ . Pharmaceutical overdose deaths, United States, 2010 . JAMA.309 , 657 – 659 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Havens JR , OserCB , LeukefeldCG . Injection risk behaviors among rural drug users: implications for HIV prevention . AIDS Care23 , 638 – 645 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Surratt H , KurtzSP , CiceroTJ . Alternate routes of administration and risk for HIV among prescription opioid abusers . J. Addict. Dis.30 , 334 – 341 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bruneau J , RoyE , ArrudaN , ZangG , Jutras-AswadD . The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users . Addiction107 , 1318 – 1127 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Conrad C , BradleyHM , BrozDet al. Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015 . MMWR. Morb. Mortal. Wkly Rep.64 , 443 – 444 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lankenau SE , KecojevicA , SilvaK . Associations between prescription opioid injection and hepatitis C virus among young injection drug users . Drugs (Abingdon. Engl).22 , 35 – 42 ( 2015 ).
   PubMedGoogle Scholar
• United Nations Office on Drugs and Crime . World Drug Report 2015 . www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf .
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality . Behavioral health trends in the United States: Results from the 2014 national survey on drug use and health. HHS Publication No. SMA 15-4927, NSDUH Series H-50 (2015) . www.samhsa.gov/data/sites/default/files/NSDUH-FRR1–2014/NSDUH-FRR1–2014.htm .
   Google Scholar
• Centers for Disease Control and Prevention . CDC Vitalsigns™: Opioid painkiller prescribing ( 2014 ). www.cdc.gov/vitalsigns/pdf/2014–2007-vitalsigns.pdf .
   Google Scholar
• Rice JB , KirsonNY , SheiAet al. The economic burden of diagnosed opioid abuse among commercially insured individuals . Postgrad. Med.126 , 53 – 58 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rice JB , KirsonNY , SheiAet al. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data . Appl. Health Econ. Health Policy12 , 435 – 446 ( 2014 ).
   PubMedGoogle Scholar
• Birnbaum HG , WhiteAG , SchillerM , WaldmanT , ClevelandJM , RolandCL . Societal costs of prescription opioid abuse, dependence, and misuse in the United States . Pain Med.12 , 657 – 667 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Katz NP , BirnbaumH , BrennanMJet al. Prescription opioid abuse: challenges and opportunities for payers . Am. J. Manag. Care19 , 295 – 302 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration . Drug Fact Sheet. Hydrocodone . www.dea.gov/druginfo/drug_data_sheets/Hydrocodone.pdf .
   Google Scholar
• Kuehn BM . Prescription drug abuse rises globally . JAMA297 , 1306 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Casati A , SedefovR , Pfeiffer-GerschelT . Misuse of medicines in the European Union: a systematic review of the literature . Eur. Addict. Res.18 , 228 – 245 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fischer B , IalomiteanuA , BoakAet al. Prevalence and key covariates of non-medical prescription opioid use among the general secondary student and adult populations in Ontario, Canada . Drug Alcohol Rev.32 , 276 – 287 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Blanch B , PearsonSA , HaberPS . An overview of the patterns of prescription opioid use, costs and related harms in Australia . Br. J. Clin. Pharmacol.78 , 1159 – 1166 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Van Amsterdam J , van den BrinkW . The misuse of prescription opioids: a threat for Europe?Curr. Drug Abuse Rev.8 , 3 – 14 ( 2015 ).
   PubMedGoogle Scholar
• Australian Institute of Health and Welfare . National Drug Strategy Household Survey detailed report 2013 (2014) . www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129549848 .
   Google Scholar
• Bramness JG , HenriksenB , PersonO , MannK . A bibliometric analysis of European versus USA research in the field of addiction. Research on alcohol, narcotics, prescription drug abuse, tobacco and steroids 2001–2011 . Eur. Addict. Res.20 , 16 – 22 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tominaga M , KawakamiN , OnoYet al. Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan: findings from the World Mental Health Japan Survey 2002–2004 . Soc. Psychiatry Psychiatr. Epidemiol.44 , 777 – 783 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration . Results from the 2013 national survey on drug use and health: summary of national findings ( 2014 ). www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf .
   Google Scholar
• Katz N , DartRC , BaileyEet al. Tampering with prescription opioid: nature and extent of the problem, health consequences, and solutions . Am. J. Drug Alcohol Abuse37 , 205 – 217 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kirsh K , PeppinJ , ColemanJ . Characterization of prescription opioid abuse in the United States: focus on route of administration . J. Pain Palliat. Care Pharmacother.26 , 348 – 361 ( 2012 ).
   PubMedGoogle Scholar
• Gasior M , BondM , MalamutR . Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations . Postgrad. Med.128 , 85 – 96 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Farré M , CamíJ . Pharmacokinetic considerations in abuse liability evaluation . Br. J. Addict.86 , 1601 – 1606 ( 1991 ).
   PubMedGoogle Scholar
• Jones JD , MogaliS , ComerSD . Polydrug abuse: a review of opioid and benzodiazepine combination use . Drug Alcohol Depend.125 , 8 – 18 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gudin JA , MogaliS , JonesJD , ComerSD . Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use . Postgrad. Med.125 , 115 – 130 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Butler SF , BlackRA , CassidyTAet al. Abuse risks and routes of administration of different prescription opioid compounds and formulations . Harm. Reduct. J.8 , 29 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Abuse-deterrent opioids – evaluation and labeling guidance for industry ( 2015 ). www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf .
   Google Scholar
• Stanos SP , BruckenthalP , BarkinRL . Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering . Mayo Clin. Proc.87 , 683 – 694 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ , OmidianH . Abuse-deterrent formulations: part 1 – development of a formulation-based classification system . Expert Opin. Drug Metab. Toxicol.11 , 193 – 204 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ , OmidianH . Abuse-deterrent formulations: part 2: commercial products and proprietary technologies . Expert Opin. Pharmacother.16 , 305 – 323 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Jang DH , RoheJC , HoffmanRS , NelsonLS . Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda) . Ann. Emerg. Med.55 , 303 – 304 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ruan X , ChenT , GudinJ , CouchJP , ChiravuriS . Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature . J. Opioid Manag.6 , 300 – 303 ( 2010 ).
   PubMedGoogle Scholar
• Badalamenti VC , BuckleyJW , SmithET . Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year . J. Opioid. Manag.8 , 115 – 125 ( 2012 ).
   PubMedGoogle Scholar
• Setnik B , RolandCL , GoliVet al. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients . J. Opioid Manag.9 , 139 – 150 ( 2013 ).
   PubMedGoogle Scholar
• Schaeffer T . Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics . J. Med. Toxicol.8 , 400 – 407 ( 2012 ).
   PubMedGoogle Scholar
• Coghill DR , CaballeroB , SorooshianS , CivilR . A systematic review of the safety of lisdexamfetamine dimesylate . CNS Drugs28 , 497 – 511 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Health Canada . Draft Guidance Document. Tamper-resistant formulations of opioid drug product submissions . www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/consultation/drug-medic/draft_guid_opioid_ebauche_ld-eng.pdf .
   Google Scholar
• Sellers EM , PerrinoPJ , ColucciSV , HarrisSC . Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential . J. Psychopharmacol.27 , 808 – 816 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Harris SC , PerrinoPJ , SmithIet al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users . J. Clin. Pharmacol.54 , 468 – 477 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dart RC , SurrattHL , CiceroTJet al. Trends in opioid analgesic abuse and mortality in the United States . N. Engl. J. Med.372 , 241 – 248 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Colucci SV , PerrinoPJ , ShramMet al. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users . Clin. Drug. Investig.34 , 421 – 429 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Burness CB , KeatingGM . Oxycodone/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation . Drugs74 , 353 – 375 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Katz N , SunS , JohnsonF , StaufferJ . ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety . J. Pain11 , 303 – 311 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Stauffer J , SetnikB , SokolowskaMet al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study . Clin. Drug Investig.29 , 777 – 790 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Webster LR , JohnsonFK , StaufferJet al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users . Drugs R D11 , 259 – 275 ( 2011 ).
   PubMedGoogle Scholar
• Tiegs G , KarimiK , BruneK , ArckP . New problems arising from old drugs: second-generation effects of acetaminophen . Expert Rev. Clin. Pharmacol.7 , 655 – 662 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bartoli A , MichnaE , HeE , WenW . Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain . Postgrad. Med.127 , 5 – 12 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wen W , TaberL , LynchSYet al. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain . J. Opioid Manag.11 , 339 – 356 ( 2015 ).
   PubMedGoogle Scholar
• Inspiron Delivery Technologies LLC . Inspirion Delivery Technologies receives FDA approval for MorphaBond™ (morphine sulfate) extended-release tablets CII, an opioid analgesic formulated with abuse-deterrent properties ( 2015 ). www.prnewswire.com/news-releases/inspirion-delivery-technologies-receives-fda-approval-for-morphabond-morphine-sulfate-extended-release-tablets-cii-an-opioid-analgesic-formulated-with-abuse-deterrent-properties-300153910.html?$G1Ref .
   Google Scholar
• Fleming AB , CarlsonDR , VaranasiRKet al. Evaluation of an extended-release, abuse-deterrent, microsphere-in-capsule analgesic for the management of patients with chronic pain with dysphagia (CPD) . Pain Pract.16 ( 3 ), 334 – 344 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gudin J , Levy-CoopermanN , KopeckyEA , FlemingAB . Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties . Pain Med.16 , 2142 – 2151 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Katz N , KopeckyEA , O’ConnorMet al. A Phase 3, multi-center, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER™ in patients with moderate-to-severe chronic low back pain . Pain156 , 2458 – 2467 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Collegium announces FDA tentative approval for Xtampza™ ER, a novel abuse-deterrent analgesic for chronic pain ( 2015 ). http://globenewswire.com/news-release/2015/11/09/785063/10155650/en/Collegium-Announces-FDA-Tentative-Approval-for-Xtampza-TM-ER-a-Novel-Abuse-Deterrent-Analgesic-for-Chronic-Pain.html .
   Google Scholar
• Setnik B , BramsonC , BassAet al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled, abuse potential study in nondependent recreational opioid users . J. Clin. Pharmacol.55 , 1351 – 1361 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Arora S , SetnikB , MichaelDet al. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain . J. Opioid. Manag.10 , 423 – 436 ( 2014 ).
   PubMedGoogle Scholar
• Rauck RL , HaleME , BassAet al. A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment . Pain156 , 1660 – 1669 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• CIMA LABS, Inc . OraGuard™: tamper-deterrent, alcohol-resistant extended release technology ( 2012 ). www.cimalabs.com/technology/oraguard .
   Google Scholar
• Darwish M , BondM , YangRet al. Assessment of alcohol-induced dose dumping with a hydrocodone bitartrate extended-release tablet formulated with CIMA® abuse deterrence technology . Clin. Drug Investig.35 , 645 – 652 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Darwish M , BondM , TracewellW , RobertsonP . Evaluation of the abuse potential of an extended release hydrocodone bitartrate tablet formulated with OraGuard™ technology in non-dependent, recreational opioid users . J. Pain14 , S74 ( 2013 ) ( Abstract 395 ).
   Web of Science ®Google Scholar
• Bond M , SchoedelC , Rabinovich-GuilattLet al. Evaluation of the relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users . J. Pain16 , S82 ( 2015 ) ( Abstract 425 ).
   Web of Science ®Google Scholar
• Hale ME , LaudadioC , YangRet al. Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain . J. Pain Res.8 , 623 – 636 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hale ME , ZimmermanTR , EyalE , MalamutR . Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain . J. Opioid Manag.11 , 507 – 518 ( 2015 ).
   PubMedGoogle Scholar
• Webster LR , SmithS , SilowskyJet al. Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labelling and scheduling . Drug Alcohol Depend.140 , e239 ( 2014 ).
   Google Scholar
• Cicero TJ , EllisMS , SurrattHL . Effect of abuse-deterrent formulation of OxyContin . N. Engl. J. Med.367 , 187 – 189 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Butler SF , CassidyTA , ChilcoatHet al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment . J. Pain14 , 351 – 358 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Coplan PM , KaleH , SandstromLet al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics . Pharmacoepidemiol. Drug. Saf.22 , 1274 – 1282 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Severtson SG , BartelsonBB , DavisJMet al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010 . J. Pain14 , 1122 – 1130 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Havens JR , LeukefeldCG , DeVeaugh-GeissAMet al. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers . Drug Alcohol Depend.139 , 9 – 17 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cicero TJ , EllisMS . Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin . JAMA Psychiat.72 , 424 – 430 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Larochelle MR , ZhangF , Ross-DegnanD , WharamJF . Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene . JAMA. Intern. Med.175 , 978 – 987 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• White AG , LeCatesJ , BirnbaumHGet al. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs . J. Opioid Manag.11 , 199 – 210 ( 2015 ).
   PubMedGoogle Scholar
• Sessler NE , DowningJM , KaleHet al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation . Pharmacoepidemiol. Drug Saf.23 , 1238 – 1246 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kirson NY , SheiA , WhiteAGet al. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States . Pain Med.15 , 1450 – 1454 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rossiter LF , KirsonNY , SheiAet al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US . J. Med. Econ.17 , 279 – 287 ( 2014 ).
   PubMedGoogle Scholar
• Cassidy TA , DasMahapatraP , BlackRAet al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation . Pain Med.15 , 440 – 451 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Cicero TJ , EllisMS , HarneyJ . Shifting patterns of prescription opioid and heroin abuse in the United States . N. Engl. J. Med.373 , 1789 – 1790 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Simon K , WorthySL , BarnesMC , TarbellB . Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety . Ther. Adv. Drug. Saf.6 , 67 – 79 ( 2015 ).
   PubMedGoogle Scholar
• Degenhardt L , BrunoR , AliRet al. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study . Drug Alcohol Depend.151 , 56 – 67 ( 2015 ).
   PubMed Web of Science ®Google Scholar